152
Participants
Start Date
February 5, 2019
Primary Completion Date
June 11, 2021
Study Completion Date
June 11, 2021
Tesetaxel
Tesetaxel plus reduced dose of capecitabine
Capecitabine
Reduced dose of capecitabine
Border Medical Oncology, Albury
New York Cancer and Blood Specialists, East Setauket
Hospital Teresa Herrera Materno-Infantil (CHUAC), A Coruña
Virginia Oncology Associates, Norfolk
Fundacion Jimenez Diaz, Madrid
Florida Cancer Specialists and Research Institute, St. Petersburg
Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers
West Cancer Center, Germantown
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Rocky Mountain Cancer Center, Lakewood
Innovative Clinical Research Institute, Whittier
Dana-Farber Cancer Institute, Boston
Hopital Maisonneuve-Rosemont, Montreal
Center Hospitalier de Montreal CHUM McPeak Sirois, Montreal
CIUSSS de Centre-Ouest-de-l'Île-de-Montréal Jewish General Hospital, Montreal
McGill University Health Center, Montreal
CHU de Quebec-University Laval, Québec
Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre, Sherbrooke
Kyungpook National University Hospital, Daegu
National Cancer Center, Goyang
Asan Medical Center, Seoul
Ajou University Hospital, Suwon
Koo Foundation Sun Yat-Sen Cancer Center, Taipei
National Taiwan University Hospital, Taipei
Gangnam Severance Hospital, Seoul
Lead Sponsor
Odonate Therapeutics, Inc.
INDUSTRY